Navigation Links
New tool to improve patient understanding of long-acting injectable antipsychotic therapies (LAT) unveiled in April issue of Psychiatry 2009
Date:5/27/2009

Titusville, NJ, May 27, 2009 A new instrument for improving patient understanding and acceptance of long-acting injectable antipsychotic therapy (LAT) has been published in the April edition of Psychiatry 2009.1 This novel, psychosocial approach encompasses Goal setting, Action planning, Initiating treatment, and Nurturing motivation (GAIN) through the use of a clinical discussion tool.

Nonadherence to oral antipsychotic medications is one of the most significant clinical challenges in psychiatry and behavioral medicine, with rates of nonadherence estimated to be as high as 50 and 75 percent in the first and second years of treatment.2,3 Despite evidence suggesting that continuous antipsychotic treatment is more effective than interrupted treatment, and the fact that LAT is strongly recommended in many cases4, the prescription of LAT remains low in the United States. GAIN was developed to assist physicians and other clinicians by providing them with an effective approach to engage patients in a discussion of the consideration of LAT and in overcoming any related barriers.

"Long acting injectable therapies have typically been reserved for the most difficult patients where nonadherence to medication has been identified as a primary obstacle, usually because of repeated relapses. Utilizing long-acting therapies administered by a healthcare professional more widely has an advantage over daily oral formulations in that healthcare professionals will know when their patients are not taking their medications before the consequences of nonadherence occur. Early intervention may well prevent relapse," said Nina R. Schooler, Ph.D. Professor of Psychiatry & Behavioral Sciences at State University of New York Downstate Medical Center. "However, it is often difficult for clinicians to discuss injectable medications with patients because of reluctance to take injections and stigma. With GAIN, we now have an effective tool to use in approaching a recommendation and have the possibility to help more patients with schizophrenia as we work together to control their symptoms."

Risperidone long-acting therapy (RLAT, or RISPERDAL CONSTA), for the treatment of symptoms of schizophrenia, is one of several long-acting injectable products available. RISPERDAL CONSTA is the only long-acting injectable form of a class of newer medicines known as atypical antipsychotics approved in the U.S. RISPERDAL CONSTA is a proven medicine with an innovative delivery system that allows it to be given every two weeks. RISPERDAL CONSTA can help reduce the symptoms that are part of schizophrenia. A number of new atypical antipsychotic LAT formulations are also expected to be available in the future, which provided further rationale for the development of GAIN.

The Schizophrenia Treatment Acceptance Response Trial (START), an initial application of the GAIN approach, evaluated acceptance of RLAT versus approach as usual. Clinicians who used GAIN found it easy to implement and almost all indicated that they would use this tool with their current and future patients.5 Rates of patient acceptance and adherence to treatment were high for both arms (and indistinguishable), which was attributed to the positive effects of more frequent contact between patients and treatment teams than is typical. Further evaluation of the efficacy of GAIN in other clinical settings is needed to understand the full utility of the tool.


'/>"/>

Contact: Sri Ramaswami
Sramaswa@its.jnj.com
908-927-7978
Golin/Harris International
Source:Eurekalert

Related medicine news :

1. Mayo study finds that team preop briefing improves communication, reduces errors
2. Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors
3. Veracord and Parasoft Partner to Improve Compliance and Reduce Cost
4. Improve Your Eye-Q
5. Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care
6. Government of Canada supports research to improve the health of future generations of Canadians
7. New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser
8. Telemedicine may improve care for school children with diabetes
9. Americans Support U.S. Working to Improve Health in Developing Countries
10. Viant Expands Relationship With HMA for Improved Healthcare Access in AZ
11. Protein that suppresses androgen receptors could improve prostate cancer diagnosis, treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology: